Beyond androgen blockade: new pathways and novel treatments in mHSPC and mCRPC
In this interview for UroToday dr. Cora Sternberg presents the latest data and ongoing clinical trials in the context of metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).